MARCELLI, LORENZO
 Distribuzione geografica
Continente #
AS - Asia 152
NA - Nord America 113
EU - Europa 53
SA - Sud America 25
AF - Africa 1
Totale 344
Nazione #
US - Stati Uniti d'America 104
SG - Singapore 79
BR - Brasile 22
BD - Bangladesh 18
HK - Hong Kong 18
IT - Italia 18
CN - Cina 17
VN - Vietnam 12
DE - Germania 10
RU - Federazione Russa 7
CA - Canada 6
FI - Finlandia 6
JP - Giappone 4
NL - Olanda 4
ID - Indonesia 3
PL - Polonia 2
AR - Argentina 1
AT - Austria 1
CH - Svizzera 1
CL - Cile 1
CO - Colombia 1
FR - Francia 1
GB - Regno Unito 1
GP - Guadalupe 1
GT - Guatemala 1
JM - Giamaica 1
PK - Pakistan 1
RO - Romania 1
SE - Svezia 1
ZA - Sudafrica 1
Totale 344
Città #
Singapore 59
Council Bluffs 24
Hong Kong 16
San Jose 13
Dallas 8
Munich 7
Ho Chi Minh City 6
New York 6
Beijing 5
Los Angeles 4
The Dalles 4
Tokyo 4
Ashburn 3
Buffalo 3
Jakarta 3
Salt Lake City 3
São Paulo 3
Turku 3
Dongguan 2
Guiyang 2
Hanoi 2
Helsinki 2
Lucca 2
Mascalucia 2
Milan 2
Naples 2
Nuremberg 2
Ottawa 2
Toronto 2
Acri 1
Amsterdam 1
Aparecida de Goiânia 1
Araguari 1
Atlanta 1
Barrie 1
Boston 1
Brooklyn 1
Caetés 1
Camaçari 1
Campinas 1
Carlisle 1
Collierville 1
Constanța 1
Da Nang 1
Del Norte 1
Duque de Caxias 1
El Cerrito 1
Engelhard 1
Feira de Santana 1
Frankfurt am Main 1
Genoa 1
Goiânia 1
Grove 1
Guaratuba 1
Guatemala City 1
Haiphong 1
Hayward 1
Houston 1
IJsselstein 1
Ipatinga 1
Itajuípe 1
Itatiba 1
Jacareí 1
Januária 1
Johannesburg 1
Joinville 1
Kingston 1
Lahore 1
Lappeenranta 1
Les Abymes 1
Londrina 1
Moscow 1
Palm Bay 1
Passo Fundo 1
Philadelphia 1
Propriá 1
Quận Mười 1
Richmond Hill 1
Rio de Janeiro 1
San Miguel de Tucumán 1
Santa Clara 1
Santiago 1
Seattle 1
Springdale 1
St. George 1
Stockholm 1
Valrico 1
Warsaw 1
Zurich 1
Totale 256
Nome #
Characterization of Super-Responder Profile in Chronic Plaque Psoriatic Patients under Guselkumab Treatment: A Long-Term Real-Life Experience 124
Successful long‐term guselkumab treatment of severe plaque psoriasis in patients with class III obesity: A case series 102
Deucravacitinib, a selective tyrosine kinase 2 inhibitor, for the treatment of moderate-to-severe plaque psoriasis 65
Real-life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: A 104-week multicenter retrospective study – IL PSO (ITALIAN LANDSCAPE PSORIASIS) 65
Totale 356
Categoria #
all - tutte 1.379
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.379


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/202420 0 0 0 0 0 0 0 0 0 6 13 1
2024/202588 3 7 3 13 6 13 6 4 7 9 9 8
2025/2026247 18 12 24 6 41 3 21 14 18 33 43 14
2026/20271 1 0 0 0 0 0 0 0 0 0 0 0
Totale 356